Olin to merge with Huntsman; shareholders to vote (NYSE: OLN)
Rhea-AI Filing Summary
Olin Corporation entered into an Agreement and Plan of Merger to combine with Huntsman Corporation in an all-stock merger of equals announced June 15, 2026. Under the deal each outstanding share of Huntsman common stock will convert into the right to receive 0.5476 shares of Olin common stock (the Exchange Ratio).
The merger can be effected either as a Direct Merger or as a two-step Subsidiary Merger depending on shareholder votes at Olin; the board of each company unanimously approved the Merger Agreement. The Combined Company will be named OlinHuntsman Corporation, governed by a ten-member board and headquartered in The Woodlands, Texas. Termination provisions include a $121,000,000 break fee in specified circumstances and a one-year Outside Date with up to two automatic three-month extensions for regulatory delays.
Positive
- None.
Negative
- None.
Insights
Merger uses standard deal mechanics, approvals, and regulatory conditions.
The Merger Agreement provides for either a Direct Merger or Subsidiary Mergers depending on Olin shareholder vote thresholds and requires approvals from Huntsman stockholders, Olin shareholders, antitrust clearances including HSR expiration, an effective Form S-4, and NYSE listing approval for the Merger Consideration.
Key legal risks include obtaining antitrust and other regulatory clearances and satisfying customary termination and closing conditions; the $121,000,000 termination fee and the Outside Date with two three-month extensions are material contractual levers to watch in subsequent public filings.
Deal economics hinge on the 0.5476 exchange ratio and choice of merger route.
The Direct Merger is described as providing added capital-structure efficiency by allowing Huntsman’s attractively priced long-term debt to remain in place; the Subsidiary Mergers offer an alternative path if voting thresholds differ. The Merger Consideration will be equity listed on the NYSE.
Material financial dependencies include shareholder approvals, regulatory clearances, and Form S-4 effectiveness; subsequent proxy and S-4 filings will disclose pro forma and synergy assumptions that investors should review when available.